| __timestamp | Alkermes plc | CymaBay Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 199905000 | 8185000 |
| Thursday, January 1, 2015 | 311558000 | 8871000 |
| Friday, January 1, 2016 | 374130000 | 9645000 |
| Sunday, January 1, 2017 | 421578000 | 12387000 |
| Monday, January 1, 2018 | 526408000 | 14381000 |
| Tuesday, January 1, 2019 | 599449000 | 19238000 |
| Wednesday, January 1, 2020 | 538827000 | 17425000 |
| Friday, January 1, 2021 | 560977000 | 23040000 |
| Saturday, January 1, 2022 | 605747000 | 25116000 |
| Sunday, January 1, 2023 | 689751000 | 51953000 |
| Monday, January 1, 2024 | 645238000 |
Igniting the spark of knowledge
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Alkermes plc and CymaBay Therapeutics, Inc. have demonstrated contrasting approaches to SG&A cost management.
From 2014 to 2023, Alkermes plc's SG&A expenses have surged by approximately 245%, reflecting their expansive operational strategies. In contrast, CymaBay Therapeutics, Inc. has maintained a more conservative growth in SG&A costs, increasing by about 535% over the same period, albeit from a much smaller base.
This data suggests that while Alkermes plc invests heavily in administrative and sales functions, CymaBay Therapeutics, Inc. adopts a more restrained approach. Investors and stakeholders should consider these trends when evaluating the companies' financial health and strategic priorities.
Breaking Down SG&A Expenses: Johnson & Johnson vs Alkermes plc
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Alkermes plc
Selling, General, and Administrative Costs: Insmed Incorporated vs CymaBay Therapeutics, Inc.
Halozyme Therapeutics, Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Cytokinetics, Incorporated and Alkermes plc
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Alkermes plc vs Evotec SE Trends and Insights
CymaBay Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Agios Pharmaceuticals, Inc.